item1.txt
The fair values of the forward contracts are recorded in the Company’s accompanying unaudited Consolidated Balance Sheets as "Prepaid expenses and other current assets" and "Accrued expenses and other current liabilities".
As of December 31, 2017, the Company had no assets or liabilities measured and recorded at fair value on a recurring basis using Level 3 inputs.
The Company adopted the guidance during the first quarter of fiscal year 2018 which had no impact on its financial position and results of operations.
The Company expects to adopt the guidance during the first quarter of fiscal year 2020 and is currently evaluating the impact of this guidance on its financial position and results of operations.
The Company expects to adopt the guidance during the first quarter of fiscal year 2021 and is currently evaluating the impact of this guidance on its financial position and results of operations.
The Company adopted the guidance during the first quarter of fiscal year 2018 which did not have a significant impact on its financial position and results of operations.
The Company has initiated the evaluation of the potential impact of adopting the new guidance on its financial position and results of operations, but has not yet completed such assessment or determined the transition method that will be used to adopt the new guidance.
Based on the preliminary assessment, the Company anticipates that the new guidance will impact the timing of revenue recognition for a portion of its life science revenue which is currently accounted for under a percentage of completion method.
The Company invests in marketable securities that are classified as available-for-sale and records them at fair value in the Company’s unaudited Consolidated Balance Sheets.
The Company reviews the marketable securities for impairment at each reporting period to determine if any of the securities have experienced an other-than-temporary decline in fair value.
The Company considers factors, such as the length of time and extent to which the market value has been less than the cost, the financial condition and near-term 
Cash equivalents of $64.2 million and less than $0.1 million, respectively, at December 31, 2017 and September 30, 2017 consist of money market funds and are classified within Level 1 of fair value hierarchy because they are valued using quoted market prices in active markets.
Cash equivalents of $9.1 million and less than $0.1 million, respectively at December 31, 2017 and September 30, 2017 consist primarily of U.S. government agency obligations, municipal securities and bank certificates of deposits with original maturities of less than 90 days and are classified within Level 2 of the fair value hierarchy because they are not actively traded.
The Company used a market participant approach to record the assets acquired and liabilities assumed in the 4titude acquisition.
The purchase price allocation is based on a preliminary valuation and is subject to further adjustments within the measurement period as additional information becomes available related to the fair value of such assets acquired and liabilities assumed.
The Company will refine such fair value estimates as new information becomes available during the measurement period.
The Company used the income approach in accordance with the excess-earnings method to estimate the fair values of customer relationships, backlog and trademarks equal to the present value of the after-tax cash flows attributable to each intangible asset.
The Company used the income approach in accordance with the relief-from-royalty method to estimate the fair value of the completed technology which is equal to the present value of the after-tax royalty savings attributable to owning that intangible asset.
During the three months ended December 31, 2017, the Company incurred $0.5 million in non-recurring transaction costs with respect to the 4titude acquisition which were recorded in "Selling, general and administrative" expenses within the accompanying unaudited Consolidated Statements of Operations.
As of December 31, 2017, the purchase price allocation is based on a preliminary valuation and subject to further adjustments when the Company obtains additional information during the measurement period.
The Company recorded a liability of $0.7 million in the purchase price allocation that represented a preacquisition contingency incurred on the acquisition date.
During the three months ended December 31, 2017, the Company recorded a goodwill increase of $39.1 million primarily related to the acquisition of 4titude which represented the excess of the consideration transferred over the fair value of the net assets acquired.
The Company accounts for certain of its investments using the equity method of accounting and records its proportionate share of the investee’s earnings in its results of operations with a corresponding increase in the carrying value of the investment.
During the three months ended December 31, 2017 and 2016, the Company recorded income of $2.2 million and $2.4 million, respectively, representing its proportionate share of UCI’s earnings.
Management fee payments received by the Company from UCI were $0.3 million during each of the three months ended December 31, 2017 and 2016.
The Company records commitment fees and other costs directly associated with obtaining line of credit financing as deferred financing costs which are presented within "Other assets" in the accompanying unaudited Consolidated Balance Sheets.
On October 4, 2017, the Company entered into a $200.0 million term loan with the lenders.
The Company incurred additional deferred financing costs of $0.4 million during the three months ended December 31, 2017.
Subject to certain conditions stated in the term loan agreement, the Company may redeem the term loan at any time at its option without a significant premium or penalty, except for a repricing transaction, as defined in the term loan agreement, which is subject to a premium of 1.00% of the loan principal amount during the first six months of the loan term.
The Company would be required to redeem the term loan at the principal amount then outstanding upon occurrence of certain events, including (i) net proceeds received from the sale or other disposition of the Company’s or guarantor’ assets, subject to certain limitations, (ii) casualty and condemnation proceeds received by the Company or the guarantor, subject to certain exceptions, (iii) net proceeds received by the Company or the guarantor from the issuance of debt or disqualified capital stock after October 4, 2017.
Commencing on December 31, 2018, the Company will be required to make principal payments equal to the excess cash flow amount, as defined in the term loan agreement.
The Company records commitment fees and other costs directly associated with obtaining term loan financing as deferred financing costs which are presented as a reduction of the term loan principal balance in the accompanying unaudited Consolidated Balance Sheets.
As of December 31, 2017, the Company was in compliance with all covenants and conditions under the term loan agreement.
During the three months ended December 31, 2017 and the fiscal year ended September 30, 2017, the Company had cumulative capitalized direct costs of $5.0 million and $4.7 million, respectively, associated with the development of software for its internal use which are included within "Property, plant and equipment, net" in the accompanying unaudited Consolidated Balance Sheets.
During the three months ended December 31, 2017, the Company capitalized direct costs of $0.3 million associated with development of software for its internal use.
The fair value of restricted stock units is determined based on the number of shares granted and the closing price of the Company’s common stock quoted on the Nasdaq Stock Market on the date of grant.
There were no annual awards of unrestricted shares of the Company stock and compensation-related restricted stock units granted to the members of the Company's Board of Directors during the three months ended December 31, 2017 and 2016, respectively.
Performance-based awards granted in fiscal year 2017 allow participants to earn 100% of a targeted number of restricted stock units if the Company’s performance meets its target for each applicable financial metric, and up to a maximum of 200% of the restricted stock units target if the Company’s performance for such metrics meets the maximum threshold.
The weighted average grant date fair value of restricted stock units granted during the three months ended December 31, 2017 and 2016 was $34.25 and $13.93, respectively.
The fair value of restricted stock units vested during the three months ended December 31, 2017 and 2016 was $19.0 million and $11.3 million, respectively.
During the three months ended December 31, 2017 and 2016, the Company remitted $6.3 million and $3.8 million, respectively, for withholding taxes on vested restricted stock units, of which $0.1 million was paid by the Company during the three months ended December 31, 2016.
There were no taxes on vested restricted stock units paid by the Company during the three months ended December 31, 2017.
During the three months ended December 31, 2017 and 2016, the Company received $6.3 million and $3.7 million, respectively, in cash proceeds from employees to satisfy their tax obligations as a result of share issuances.
As of December 31, 2017, the unrecognized compensation cost related to restricted stock units that are expected to vest is $33.2 million and will be recognized over an estimated weighted average service period of approximately 1.9 years.
The Company maintains an Employee Stock Purchase Plan that allows its employees to purchase shares of common stock at a price equal to 85% of the fair market value of the Company’s stock at the beginning or the end of the semi-annual period, whichever is lower.
There were no shares purchased by employees or issued by the Company under the employee stock purchase plan during the three months ended December 31, 2017 and 2016.
The Company had one customer within the Brooks Semiconductor Solutions Group segment that accounted for 10% or more of its consolidated revenue, at 11%, during each of the three months ended December 31, 2017 and 2016.
As of December 31, 2017 and September 30, 2017, the Company had no customers that accounted for 10% or more of the Company’s total receivables.
The Company has non-cancellable contracts and purchase orders for inventory of $128.6 million and $122.0 million, respectively, at December 31, 2017 and September 30, 2017.


item2.txt
Cash Flows and Liquidity- Cash and cash equivalents and marketable securities were $231.9 million at December 31, 2017 as compared to $104.3 million at September 30, 2017.
The increase in cash and cash equivalents and marketable securities of $127.6 million was primarily attributable to cash inflows of $197.6 million related to proceeds from the term loan and cash inflows of $3.2 million generated from our operating activities, partially offset by cash outflows related to acquisition payments of $65.1 million, dividend payments of $7.1 million made to our shareholders during the first quarter of fiscal year 2018, as well as capital expenditures of $2.7 million.
Cash inflows of $3.2 million generated from operating activities during the three months ended December 31, 2017 were comprised primarily of earnings of $27.1 million, including net income of $16.5 million and the impact of non-cash related charges of $10.6 million, partially offset by uses of cash of $23.9 million related to the changes in our operating assests and liabilities, net of acquisitions.
Please refer to "Liquidity and Capital Resources" section below for a detailed discussion of our liquidity and changes in cash flows for the three months ended December 31, 2017 compared to the three months ended December 31, 2016.
We reported revenue of $189.3 million for the three months ended December 31, 2017, compared to $160.0 million for the corresponding period of the prior fiscal year, an increase of $29.4 million, or 18%.
The impact of changes in foreign currency exchange rates favorably affected revenue by $2.4 million during the three months ended December 31, 2017 when compared to the corresponding period of the prior fiscal year.
Our Brooks Life Sciences segment reported revenue of $47.4 million for the three months ended December 31, 2017 compared to $33.3 million for the corresponding period of the prior fiscal year.
Brooks’ Life Sciences internal revenue growth was favorably affected by foreign currency exchange rates which increased revenue by $0.5 million during the three months ended December 31, 2017 as compared to the corresponding period of the prior fiscal year.
Revenue generated outside the United States amounted to $117.2 million, or 62% of total revenue, for the three months ended December 31, 2017 compared to $106.8 million, or 67% of total revenue, for the corresponding period of the prior fiscal year.
We reported gross margins of 39.7% for the three months ended December 31, 2017 compared to 35.6% for the corresponding period of the prior fiscal year.
Cost of revenue for the three months ended December 31, 2017 and 2016 included $0.9 million and $1.0 million, respectively, of charges for amortization related to completed technology, as well as $1.2 million and $0.1 million, respectively, of charges related to the sale of inventories obtained in acquisitions to which a step-up in value was applied in purchase accounting.
Our Brooks Semiconductor Solutions Group segment reported gross margins of 41.9% for the three months ended December 31, 2017 as compared to 35.9% for the corresponding period of the prior fiscal year.
Cost of revenue during the three months ended December 31, 2017 and 2016 included $0.5 million and $0.6 million, respectively, of amortization related to completed technology.
Our Brooks Life Sciences segment reported gross margins of 33.2% for the three months ended December 31, 2017 as compared to 34.4% for the corresponding period of the prior fiscal year.
Such charges were $1.2 million during the three months ended December 31, 2017 compared to $0.1 million during the corresponding period of the prior fiscal year.
Cost of revenue during each of the three months ended December 31, 2017 and 2016 also included $0.4 million of amortization related to completed technology.
Research and development expenses were $13.2 million during the three months ended December 31, 2017 as compared to $10.8 million during the corresponding period of the prior fiscal year.
The increase of $2.4 million reflects higher costs of $1.4 million within the Brooks Semiconductor Solutions Group segment and $1.0 million within the Brooks Life Sciences segment which were primarily attributable to higher employee-related costs and project spending to support new product development and the growth of our business.
Gain on Settlement of Equity Method Investment- During the three months ended December 31, 2016, we recognized a gain of $1.8 million on the settlement of the equity method investment in BioCision which was included as a part of the non-cash consideration for an acquisition of Cool Lab in November 2016.
Interest Expense- During the three months ended December 31, 2017, we recorded interest expense of $2.2 million which was primarily related to the term loan originated on October 4, 2017.
The increase of $1.4 million was primarily attributable to an increase in foreign currency exchange losses during the three months ended December 31, 2017 as compared to the corresponding period of the prior fiscal year.
The Company recorded a discrete benefit of $0.7 million in the three months ended December 31, 2017 due to the impact of the U.S. rate change on its net U.S. deferred tax liabilities.
During the three months ended December 31, 2017, we recorded income of $2.2 million from our equity method investments as compared to $1.9 million during the corresponding period of the prior fiscal year.
The increase of $0.2 million was primarily attributable to higher income generated from ULVAC Cryogenics, Inc., or UCI, during the first quarter of fiscal year 2018 as compared to the corresponding period of the prior fiscal year.
During the three months ended December 31, 2016, we incurred losses of $0.5 million from our investment in BioCision which was settled during the first quarter of fiscal year 2017 as a part of the non-cash consideration for the acquisition of Cool Lab in November 2016.
We believe that our current cash balance, marketable securities portfolio, access to the revolving line of credit, as well as to debt and capital markets along with cash flows from operations will satisfy working capital, financing activities, debt service and capital expenditure requirements for the next twelve months.
At December 31, 2017, the outstanding term loan principal balance was $200.0 million, net of unamortized deferred financing costs of $2.7 million.
Cash and cash equivalents and marketable securities were $231.9 million at December 31, 2017 as compared to $104.3 million at September 30, 2017.
The increase in cash and cash equivalents and marketable securities of $127.6 was primarily attributable to cash inflows of $197.6 million related to proceeds from the term loan and cash inflows of $3.2 million generated from our operating activities, partially offset by cash outflows related to acquisitions of $65.1 million, dividend payments of $7.1 million made to our shareholders during the first quarter of fiscal year 2018, as well as capital expenditures of $2.7 million.
Cash flows provided by operating activities were $3.2 million during the three months ended December 31, 2017, comprised primarily of earnings of $27.1 million, including net income of $16.5 million and the impact of non-cash related charges of $10.6 million, partially offset by the uses of cash of $23.9 million related to the changes in our operating assets and liabilities.
The changes in operating assets and liabilities that resulted in a use of cash consisted primarily of an increase in accounts receivable as a result of higher revenue and timing of billings, a decrease in accrued compensation and tax withholdings as a result of year-end cash incentive bonus payments and an increase in inventory levels to support the growth of our business.
Cash flows provided by operating activities were $18.7 million during the three months ended December 31, 2016 and comprised primarily of earnings of $18.9 million, including net income of $13.9 million and the impact of non-cash related charges of $5.0 million, partially offset by the uses of cash of $0.2 million related to the changes in our operating assets and liabilities.
Cash used in investing activities of $9.3 million during the three months ended December 31, 2016 included a cash payment of $5.3 million for the acquisitions and $3.8 million of capital expenditures.
Capital expenditures were $2.7 million during the first quarter of fiscal year 2018 as compared to $3.8 million during the corresponding period of the prior fiscal year.
The decrease of $1.1 million was primarily attributable to lower investments made in our capital asset infrastructure during the first quarter of fiscal year 2018 compared to the corresponding period of the prior fiscal year.
Please refer to Note 8, "Debt" in the Notes to the unaudited consolidated financial statements included in Item 1 "Consolidated Financial Statements" on this Form 10-Q for further information on future minimum principal payment obligations under the term loan as of December 31, 2017.


item3.txt
Most of these transactions or balances are denominated in Euros, British Pounds and a variety of Asian currencies.
Sales in currencies other than the U.S. dollar were approximately 29% and 37% of our total sales, respectively, during the three months ended December 31, 2017 and 2016.
Such balances were approximately $129.5 million and $51.6 million, respectively, at December 31, 2017 and September 30, 2017, and related to the Euro, British Pound and a variety of Asian currencies.
We incurred foreign currency losses of $2.0 million and $0.5 million, respectively, during the three months ended December 31, 2017 and 2016, which related to the currency fluctuation on these balances between the time the transaction occurred and the ultimate settlement of the transaction.


part2.txt
The timing and amount of any shares repurchased are based on market and business conditions, legal requirements and other factors and may be commenced or suspended at any time at our discretion.
There were no shares repurchased under this program during the three months ended December 31, 2017.


